Multiple Sclerosis Therapeutic Market Forecast To Show Huge Growth

Multiple Sclerosis Therapeutic Industry

The global multiple sclerosis therapeutic market size is expected to reach USD 38.62 billion by 2030, registering a CAGR of 5.9% from 2024 to 2030, according to a new report by Grand View Research, Inc.

The presence of high unmet clinical needs in developing regions is one of the highest impact rendering drivers of the multiple sclerosis therapeutics market. Many organizations over the globe are actively involved in spreading awareness among people regarding progressive multiple sclerosis and the symptoms associated with it. Some notable examples include the National Multiple Sclerosis Society (NMSS) in the U.S., Multiple Sclerosis International Federation in Canada, European Multiple Sclerosis Platform (EMSP), and the Multiple Sclerosis Society (MSC).

Reimbursement programs are also anticipated to enhance the penetration of multiple sclerosis drugs. For instance, In June 2014, Biogen Idec Canada, announced that its TECFIDERA drug for the treatment of MS is available for reimbursement in British Colombia through B.C PharmaCare.

The introduction of novel therapeutics with minimal dosage requirement and cost-effectiveness is further expected to favor market growth. For, instance Lemtrada by Sanofi needs to be administered 3-5 times per year as compared to Copaxone, which requires daily administration.

Gather more insights about the market drivers, restrains and growth of the Global Multiple Sclerosis Therapeutic market

Multiple Sclerosis Therapeutic Market Segments Highlights:

• The declining revenue of Copaxone, Gilenya, Avonex, and Tysabri is forecasted by considering the factors such as limited usage rates of these drugs owing to the availability of highly potent FDA-approved oral drugs, Aubigio and Tecfidera
• Immunosuppressant,on the other hand, is expected to witness significant growth of over 18.0%. The presence of a strong drug pipeline and its expected commercialization in the coming six years are some factors expected to drive market growth
• In 2023, the injectable drugs market held the largest share owing to high prescription rates & price
• North America dominated the global multiple sclerosis therapeutic market with a share of 38.3% in 2023. The increasing prevalence of multiple sclerosis, the introduction of new drugs, and high prices of drugs, such as Tysabri and Aubagio in the U.S., are some factors responsible for its dominance.

Multiple Sclerosis Therapeutic Market Report Segmentation

Grand View Research has segmented the global multiple sclerosis therapeutics market based on drug class, route of administration, distribution channel, and region:

Multiple Sclerosis Therapeutic Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• Immunosuppressants
• Immunostimulants

Multiple Sclerosis Therapeutic Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Oral
• Injectable
• Others

Multiple Sclerosis Therapeutic Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies
• Retail Pharmacies
• E-Commerce

Multiple Sclerosis Therapeutic Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Norway
  • Denmark
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • UAE
  • South Arabia
  • South Africa
  • Kuwait

Key Multiple Sclerosis Therapeutic Company Insights

• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Biogen
• Bayer AG
• Sanofi
• Hoffmann-La Roche Ltd
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Takeda Pharmaceutical Company Limited.
• Horizon Therapeutics plc

Order a free sample PDF of the Multiple Sclerosis Therapeutic Market Intelligence Study, published by Grand View Research.